The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity

Official Title: “The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity”

The purpose of the study is to evaluate the effects of a single-dose of Wellbutrin XL (bupropion hydrochloride) on reward processing.

A cardinal feature of Major Depressive Disorder is anhedonia, which is a lack of pleasure in normally enjoyable activities. In order to understand reward processing in depressed individuals it is also necessary to study reward processing in people who are not depressed.

Bupropion, the active drug in the anti-depressant Wellbutrin XL, has been shown to increase brain reward functioning in animals. The goal of the present study is to investigate the effects of Wellbutrin XL administered to psychiatrically healthy individuals as they perform a computer task known to assess reward processing.

Intervention(s) in this Clinical Trial

• Drug: Bupropion
  • 150 mg of bupropion administered 5 hours before fMRI scanning
• Drug: Placebo
  • Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)

Arms, Groups and Cohorts in this Clinical Trial

• Placebo Comparator: Placebo
• Active Comparator: Bupropion

Primary Measures

• Whether an acute dose of bupropion vs. placebo differentially affects the neurobiology and behavior of reward processing in depressed participants.
  • Time Frame: 1 day
    Safety Issue?: Yes

Inclusion Criteria:

• Absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse)
• Non-Smoker
• Right-handed (Chapman and Chapman 1987)
• Ability to provide informed consent

Exclusion Criteria:

• Predisposition to seizure (e.g. family history of a seizure disorder, history of head trauma) or current use of medications that lower the seizure threshold
• History or current diagnosis of anorexia or bulimia
• Alcohol or substance abuse within the past year
• Current usage of Wellbutrin or Zyban or other drugs that contain bupropion
• Recent discontinuation of alcohol or sedatives (including benzodiazepines)
• Use of (in the last 2 weeks) medications that may have antidepressant properties (ex.
• some herbal supplements)
• Known allergies to bupropion
• Currently lactating, pregnant or believe you are likely to be pregnant (enrolled subjects who are not using reliable contraception and have engaged in sexual intercourse since their last menstrual period will be given a self-administered pregnancy test.)
• Left-handed/ambidextrous
• Evidence of neurological illness
• Serious suicide or homicide risk
• Concomitant medications other than those listed in the exclusion criteria will be considered on an individual basis. Oral contraceptives will be allowed.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 64 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Affective Neuroscience Laboratory Other

Overall Clinical Trial Officials and Contacts

Diego A Pizzagalli, PhD Principal Investigator Harvard University  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00205946

Study ID Number: 2004-P-002234-1

ClinicalTrials.gov Identifier: NCT00205946

Health Authority: United States: Federal Government

Affective Neuroscience Laboratory, Department of Psychology, Harvard University